Content about Gastro-

March 21, 2013
Study finds norovirus leading cause of acute gastroenteritis in infants, young children as rotavirus declines

Norovirus has emerged as the leading cause of gastroenteritis - inflammation of the stomach and intestines - in children younger than 5 years, according to a new study.

ATLANTA — Norovirus has emerged as the leading cause of gastroenteritis — inflammation of the stomach and intestines — in children younger than 5 years, according to a new study.

February 25, 2013
FDA approves Bayer's Stivarga for gastrointestinal stromal tumors

The Food and Drug Administration has approved a new drug made by Bayer HealthCare Pharmaceuticals for treating tumors of the digestive system, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Bayer HealthCare Pharmaceuticals for treating tumors of the digestive system, the agency said Monday.

The FDA announced the approval of Stivarga (regorafenib) for gastrointestinal stromal tumors that could not be removed through surgery or had spread to other parts of the body and were no longer responding to treatment with Novartis' Gleevec (imatinib) or Pfizer's Sutent (sunitinib).

September 5, 2012
Bayer, Onyx seek approval for gastrointestinal tumor drug

Bayer HealthCare and Onyx Pharmaceuticals are seeking approval for a new drug to treat tumors of the gut, the companies said.

WAYNE, N.J. — Bayer HealthCare and Onyx Pharmaceuticals are seeking approval for a new drug to treat tumors of the gut, the companies said.

Bayer and Onyx announced the submission to the Food and Drug Administration of an application seeking approval for regorafenib in patients with gastrointestinal stromal tumors, or GIST. Bayer developed the drug and formed a partnership with Onyx in 2011, whereby Onyx will receive a royalty on future global net sales of the drug in cancer-related indications. Both companies will promote the drug in the United States.